. Parathyroid hormonerelated protein-(38-64) regulates lung cell proliferation after silica injury.
INSTILLATION OF SILICA into the lungs of rats produces a model of acute silicosis marked by granulomatous inflammation, fibrosis, accumulation of surfactant phospholipids, and alveolar type II cell hyperplasia and hypertrophy (18, 24, 25) . One dose of silica causes type II cells to begin dividing within a few days and to continue dividing for many weeks or longer (24, 25, 27) . Type II cell hyperplasia also is a prominent characteristic of silicosis in Syrian hamsters, guinea pigs, and humans (8, 13, 29) . Little is known about what growth factors stimulate type II cell proliferation after silica exposure. Bronchoalveolar lavage (BAL) fluid from patients with silicosis has increased mitogenic activity for rat type II cells compared with BAL from normal humans (16) , but the identity of those factors is unknown. Candidates include platelet-derived growth factor, fibroblast growth factor (FGF), insulin-like growth factor-I (IGF-I), and epidermal growth factor, which are all increased after silica exposure (16, 22) .
Parathyroid hormone-related protein (PTHrP), best known as the mediator of humoral hypercalcemia of malignancy, could be a regulator of alveolar epithelial cell growth in silicosis. Type II epithelial cells produce and secrete PTHrP, and they express the type I PTH/ PTHrP receptor. Type II cells respond to changes in ambient PTHrP concentration with alterations in function and growth (10) (11) (12) . The amino-terminal portion of the molecule, PTHrP-(1-34), stimulates characteristics that are typical of the differentiated type II cell phenotype, such as production of disaturated phosphatidylcholine (11) . Treating cultured type II cells with neutralizing PTHrP antibodies induces type II cell proliferation in vitro, whereas instilling the same antibodies into normal lungs causes proliferation in vivo (12) . Thus PTHrP is an autocrine type II cell growth inhibitor. Our studies have shown that PTHrP also is involved in the epithelial response to hyperoxic lung injury. Lung PTHrP levels are decreased in rats after injury by 85% oxygen, concurrent with increased expression of proliferating cell nuclear antigen (PCNA) and increased incorporation of 5-bromo-2-deoxyuridine (BrdU) into DNA in alveolar type II cells (9) . Instillation of PTHrP-(1-34) into rat lungs exposed to 85% oxygen reduces BrdU incorporation. These data suggest that a fall in lung PTHrP is a common response to injury and that reduced levels of PTHrP-(1-34) may contribute to the type II cell growth response.
From the preceding discussion, we would predict that lung PTHrP levels would fall after silica-induced lung injury and that PTHrP- would have a role in regulating this process. Lung PTHrP expression has not been evaluated in lung injury models other than those induced by hyperoxia. Furthermore, portions of the PTHrP molecule besides PTHrP-(1-34) are known to exert biological effects. For example, PTHrP-(38-95) activates intracellular calcium signaling pathways in several cell types (33) . PTHrP-(67-86) inhibits mitogenesis in 8701-BC breast carcinoma cells and stimulates placental calcium transport in sheep (3, 17) , whereas a sequence contained within PTHrP-(107-139) inhibits osteoclastic bone resorption (36) , and PTHrP-(140-173) regulates chondrocyte function (7) . No studies have investigated the pulmonary effects of peptides derived from PTHrP other than PTHrP- . Thus the goals of this study were to investigate changes in lung PTHrP levels after silica-induced lung injury and to evaluate the effects of several PTHrPderived peptides on type II cell proliferation after silica injury.
METHODS

Animals
Male pathogen-free Sprague-Dawley rats were ordered from Charles River (Hollister, CA). The institutional animal care and use committee approved these studies.
Silica Lung Injury
Silica (Min-U-Sil; Pennsylvania Glass Sand, Los Angeles, CA) was boiled in 1 N HCl, washed, dried, suspended in PBS, and autoclaved. Suspensions were sonicated for 10 min before use (4) . Rats (250-350 g) were anesthetized with 2-4% isoflurane, intubated orally with a #14 plastic intravenous catheter, instilled with 10 mg of silica in 1 ml of suspension, recovered, and extubated. Control animals received PBS alone. At the end of the experimental period (0, 4, 7, 14, and 28 days), we anesthetized rats with 80 mg/kg intraperitoneal pentobarbital sodium and exsanguinated them by cutting the renal artery. Normal saline was perfused through the pulmonary artery to clear the lungs of blood, and the lungs were removed. The lungs were weighed and homogenized in PBS with protease inhibitors (3:1 vol/wt) as described previously (9) . The homogenate was centrifuged at 16,000 g for 1 h at 4°C, and the supernatant was frozen at Ϫ70°C for subsequent assay.
PTHrP peptide treatment. After establishing the time course for changes in PTHrP expression after silica injury, we instilled additional rats with silica and treated them with PTHrP peptide. The duration of these experiments was 4 days. The instillate consisted of 10 mg of silica and 15 g of PTHrP-(1-34), PTHrP-(38-64), PTHrP-(67-86), or PTHrP-(107-138) (Peninsula Labs, Torrance, CA) in 1 ml of 0.05% BSA in PBS. Rats also received subcutaneous injections of 5 g of the same peptide in 100 l of BSA-PBS at the time of instillation and daily for 3 days. As controls, rats received silica in BSA-PBS as the instillate and daily injections of BSA-PBS. In a second control group, rats received the PTHrP peptide in BSA-PBS without silica followed by daily injections of the peptide. Four days after instillation, rats were anesthetized and killed as described above.
Lung preparation. The right lung was removed and lavaged with five 4-ml aliquots of PBS before homogenization. Inflammatory cells were separated from BAL by centrifugation and resuspended in 1 ml for cell counts. Cytospin preparations were stained with xanthene and thiazine dyes (Newcomer Supply, Middleton, WI), washed, air-dried, and mounted for differential counts. The cell-free BAL was frozen at Ϫ70°C for subsequent assay. The left lung was fixed by tracheal instillation of 6 ml of 4% paraformaldehyde in 0.1 M phosphate buffer at 37°C, pH 7.4, embedded in paraffin, and processed for hematoxylin and eosin staining, cytochemical staining for alkaline phosphatase, or immunocytochemical staining. In some animals, the left lung was fixed by instillation with 2.5% glutaraldehyde and 4% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, embedded in Epon, postfixed in osmium tetroxide, stained 5 min in 4% ethanolic uranyl acetate, and briefly contrasted with bismuth lead citrate. Thin sections (80 nm) were examined and recorded using a Zeiss electron microscope.
Type II cell preparation. Type II cells were isolated from silica-injured and uninjured rat lungs by the method of Dobbs as described previously (5, 10) . Cell harvest occurred 1 day after silica or PBS instillation. Briefly, the lungs were perfused and lavaged to remove airway inflammatory cells, digested with low concentrations of elastase, minced, filtered through gauze and nylon screen filters, and washed free of protease. Type II cells were isolated from the crude cell preparation by panning on IgG-coated plates. Cell counts were determined with a hemocytometer, and cell viability was assessed by trypan blue exclusion. Purity was determined by the use of Papanicolaou staining of air-dried smears. The purified type II cell population contained 65 Ϯ 4% type II cells with Ͼ95% viability. The yield, purity, and viability of type II cells did not vary among PTHrP-(38-64)-treated and control silica-injured rats.
rTI 40 Dot Blots BAL levels of rTI40, a 40-kDa rat alveolar type I cellspecific membrane, increase in association with morphological injury to type I cells due to hyperoxia, nitrogen dioxide exposure, or bacterial pneumonia (19) (20) (21) . BAL rTI 40 levels were measured with an enzyme-linked immunosorbent assay-based assay described by McElroy and colleagues (19) (20) (21) . The monoclonal antibody to rTI 40 was kindly supplied by Leland Dobbs (San Francisco, CA). BAL samples were applied to Immobilon-P membranes (Millipore, Bedford, MA) using a dot-blot apparatus (1-10 g protein/well). Membranes were then blocked for 2 h at room temperature with 0.4% nonfat milk powder in tris(hydroxymethyl)aminomethane-buffered saline [TBS (20 mM Tris base, 154 mM NaCl, pH 8.2)], washed with TBS containing 0.05% Tween-20 (TBS-T) five times, incubated with monoclonal antibody against rTI 40 diluted 1:10 in 20 mM NaHCO3 for 2 h, and then washed again with TBS-T before incubation with sheep anti-mouse secondary antibody conjugated to horseradish peroxidase (1: 25,000 dilution; Calbiochem, La Jolla, CA). Membrane blots were once again washed with TBS-T five times before being developed with enhanced chemiluminescence reagents (NEN Life Sciences) and exposed to X-OMAT AR-5 film (NEN Life Sciences) for 2-3 min. Semiquantitative data from the dot blots were obtained by densitometry readings. The readings were normalized to a positive control consisting of homogenates of normal rat lung. Results were expressed as relative densitometry units per milligram of protein.
Radioimmunoassay of PTHrP
PTHrP levels were determined in the lung supernatants with a previously described radioimmunoassay using an antibody to PTHrP-(109-141) (12, 30) .
Immunohistology
Lung sections (5 m) were deparaffinized in xylene and hydrated through a graded ethanol series. The process to stain prosurfactant apoprotein C (SP-C) began by heating sections at 90°C in 10 mM sodium citrate buffer, pH 6.0, for antigen retrieval. Nonspecific protein binding was blocked with 10% goat serum. Sections were incubated with primary antibody for PCNA (1:20, PC10; Dako, Carpinteria, CA) or human pro-SP-C (1:1,000; Chemicon, Temecula, CA) diluted in 0.5% BSA in PBS overnight at 4°C. Immunoreactivity was absent when primary antibody was omitted on sections (not shown). Biotinylated goat anti-mouse antibody (Calbiochem), diluted at 1:33 with 0.01% goat serum in PBS, was applied for 25 min. Staining was completed by incubation with streptavidin-alkaline phosphatase or horseradish peroxidase conjugates. Chromogens were fast blue or vector red alkaline phosphatase substrates (Vector Laboratories, Burlingame, CA) or 3,3Ј-diaminobenzidine tetrahydrochloride. Staining experiments were performed on lung sections from at least three animals per time point. Staining was repeated at least once for each animal. PCNA immunoreactivity was quantified as a function of experimental manipulation by a blinded observer who counted the number of stained corner cells in 75 high-power fields (hpf, ϫ100) per section.
Cell Cycle Determinations
Cell cycle status determination based on DNA analysis was performed on type II cells and BAL cells isolated one day after silica injury. Pellets containing 3 ϫ 10 6 cells were fixed in an equal volume of 100% ethanol, resuspended in a solution of 50 g/ml propidium iodide and 1.3 mg/ml RNase in PBS, and analyzed on a Coulter Elite flow cytometer (Beckman Coulter Electronics, Miami, FL). Additional cells were fixed in 1% paraformaldehyde and then stained by fluorescent terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) using a kit from Promega (Madison, WI). TUNEL-positive cells were quantified by flow cytometry. 
H]Thymidine Incorporation
Type II cells were plated at 4 ϫ 10 5 cells/well in 24-well plates and allowed to adhere in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) for 24 h. The number of viable adherent cells, quantified by colorimetric assay of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, did not vary between rats treated with PTHrP-(38-64) and rats treated with PBS (data not shown). Cells were washed in PBS and incubated in fresh DMEM-10% FBS with 0.5 Ci of [ 3 H]thymidine/well for 24 h. The supernatant was removed, and cells were washed three times with ice-cold PBS, three times with 1 ml/well of cold 10% trichloroacetic acid, and then lysed in 0.5 ml 1 N NaOH. The cell lysate was counted in scintillation fluid in a Beckman scintillation counter (Beckman Coulter, Fullerton, CA).
Alkaline Phosphatase Cytochemical Stain
Endogenous alkaline phosphatase activity was evaluated as a marker for type II cells as described for silica-injured lungs by Miller and colleagues (23) . Lung sections were deparaffinized, washed in TBS, and incubated for 30 min with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium in 100 mM Tris ⅐ HCl, pH 9.5, using the alkaline phosphatase substrate kit IV from Vector Laboratories. Sections were washed in TBS and deionized water, dehydrated, and coverslipped. Sections from three random blocks were analyzed, and the results were combined for each animal. Alkaline phosphatase staining was quantified as a function of experimental manipulation by evaluating the number of stained corner cells/alveolus. This number, expressed as a percentage, ranged from Ͻ100% (signifying that not all alveoli had stained cells) to almost 200% (signifying two alkaline phosphatase-stained cells, on average, per alveolus). The percentage of alkaline phosphatase-positive cells/alveolus was scored on an ordinal scale, with Ͻ2, 2-25, 26-50, 51-75, 76-100, 101-125, 126-150, 151-175, and 176-200% corresponding to scores of 0-8, respectively. Alkaline phosphatase expression in type II cells and lung inflammatory cells was compared by staining cytospin preparations of freshly isolated type II cells and BAL cells from silica-injured rats.
Statistics
Lung homogenate PTHrP levels, BAL rTI40 levels, PCNA immunoreactivity, and alkaline phosphatase staining were compared among groups by nonparametric ANOVA. Lung weights, BAL total protein contents, cell counts, thymidine incorporation, and percentage of S phase cells were compared among groups by ANOVA. The Tukey and Dunn tests were used for post hoc pair-wise parametric and nonparametric comparisons, respectively (35) . Data are reported as means Ϯ SE. Significance was accepted if the probability of a type I error was Ͻ0.05.
RESULTS
Lung Injury and Inflammation After Silica
Comparison of untreated control and silica-injured lungs. Lung weights rose progressively with time after silica instillation and were significantly greater than in control lungs instilled with PBS (Table 1) . BAL total protein was significantly increased after 4 days of silica injury, 280 Ϯ 40 g/ml (n ϭ 12), compared with lungs treated with PBS, 170 Ϯ 40 g/ml (n ϭ 16, P Ͻ 0.01). Silica treatment increased BAL macrophage and neutrophil counts above control values from 1.7 Ϯ 0.1 to 2.8 Ϯ 1.3 ϫ 10 6 cells/ml and from 0.1 Ϯ 0.1 to 5.0 Ϯ 2 ϫ 10 5 cells/ml, respectively (P Ͻ 0.05). BAL levels of rTI 40 were greater 4 days after silica than in control lungs, 201 (140, 240) [median (interquartile gap)] vs. 49 (8, 165) relative units, but the difference did not reach the level for statistical significance (P ϭ 0.06). Lungs 4 days after silica treatment showed a mixed histiocytic infiltration with predominant macrophages and occasional neutrophils (Fig. 1) . Effects of PTHrP treatment. Table 2 summarizes several indexes of lung injury and inflammation as a function of lung injury and PTHrP peptide treatment. The effects of PTHrP peptide treatment combined with silica lung injury were analyzed by two-way ANOVA. Injury had a significant effect on lung weight, BAL total protein concentration, and BAL neutrophil counts (P Ͻ 0.01), but PTHrP treatment did not, and interaction effects were not significant. Lung injury and PTHrP treatment both had significant effects on macrophage counts with a significant interaction effect (P Ͻ 0.01). In silica-injured animals, PTHrP-(38-64) and PTHrP-(107-138) increased macrophage counts compared with the PBS treatment ( Table 2 ). All indexes of injury and inflammation were significantly greater in silica-injured lungs than in control lungs (Table 2) . rTI 40 levels did not vary among treatment groups in either uninjured control lungs or silica-injured lungs (Fig. 2) . rTI 40 in silica-injured animals treated with PTHrP-(107-138) was significantly greater than in uninjured animals treated with PTHrP-(107-138) (P Ͻ 0.05). Body weights did not vary among the groups. PTHrP peptide treatment did not cause significant differences in any of the indexes of injury or inflammation in uninjured control lungs.
Lung PTHrP Levels After Silica Injury
Lung PTHrP levels decreased from 43,111 Ϯ 9,685 pg/ml in control animals to 16,468 Ϯ 3,281 pg/ml 4 days after silica, a 60% decline (P Ͻ 0.05). Levels rose progressively after 4 days and were not significantly different from control at 7, 14, and 28 days (Fig. 3) . Lung PTHrP levels did not change over this same period in animals instilled with PBS. Because of questions about how PTHrP levels should be normalized in the setting of lung injury, we also analyzed total lung PTHrP normalized to lung weight. The results of the analysis were unchanged. At 4 days, the silica-injured lungs contained 62,613 Ϯ 12,690 pg PTHrP/g lung compared with 126,526 Ϯ 17,253 in control uninjured lung (P Ͻ 0.05).
Effect of PTHrP Peptide on Cell Proliferation in Silica-Injured Lungs
PCNA expression in injured lung. PCNA immunoreactivity was present in corner cells in rats at 4 days (Fig. 4A ) and longer after silica instillation. At 4 days, the fraction of PCNA-positive corner cells was significantly greater in silica-injured animals treated with PTHrP-(38-64) than in the other groups (Figs. 4B and 5). Other than the group treated with PTHrP-(38-64), the silica-injured groups did not display greater lung PCNA expression than the control, uninjured animals. Because PTHrP-(38-64) increased PCNA staining in silica-injured lungs, we carried out additional experiments to examine its effects on cell proliferation. We performed cell cycle analysis and [ 3 H]thymidine incorporation assays on type II cells isolated from injured lungs treated with PTHrP-(38-64) or PBS. We also investigated type II cell numbers in silica-injured, PTHrP-treated lungs.
Cell cycle distributions. Silica injury increased the percentage of type II cells in S phase to 11.9 Ϯ 1.7%, eightfold greater than in cells from uninjured lungs (Table 3 , P Ͻ 0.05). PTHrP-(38-64) treatment nearly doubled that figure, a significant increase compared with both uninjured lungs and injured, PBS-treated lungs. The percentage of cells in G2/M phase did not vary significantly among uninjured, injured PBStreated, and injured PTHrP-(38-64)-treated rats, respectively. The fraction of proliferating BAL inflammatory cells was much lower than for type II cells. Only 3.1 Ϯ 1.1% and 1.4 Ϯ 0.6% of BAL cells from injured lungs were in S phase and G2/M, respectively, with no significant difference between PBS and PTHrP treatment groups.
Fluorescent TUNEL. The percentages of freshly isolated type II cells that were TUNEL positive were Fig. 3 . Lung PTHrP expression after silica injury. Sprague-Dawley rats were instilled with 10 mg silica/1 ml PBS or PBS alone and followed for the time shown. Lungs were homogenized in a 3:1 vol/wt ratio of PBS with protease inhibitors, and PTHrP was measured by RIA in the supernatant. Lung PTHrP levels decreased from 43,111 Ϯ 9,685 pg/ml in control animals to 16,468 Ϯ 3,281 pg/ml 4 days after silica, a 60% decline. Levels rose progressively after 4 days and were not significantly different from control at 7, 14, and 28 days. Lung PTHrP levels did not change over this same period in animals instilled with PBS. The results of the analysis were unchanged by normalizing total lung PTHrP to lung weight. At 4 days, the silicainjured lungs contained 62,613 Ϯ 12,690 pg PTHrP/g lung compared with 126,526 Ϯ 17,253 in control uninjured lung (*P Ͻ 0.05). Other than the group treated with PTHrP-(38-64), the silica-injured groups did not display greater PCNA expression than the control, uninjured animals. Data represent 4-9 animals/group. similar in injured lungs treated with PBS and PTHrP-(38-64), 11.9 Ϯ 4.6% and 11.1 Ϯ 2.5%, respectively.
[ 3 H]Thymidine incorporation. Type II cells from silica-injured lungs treated with PTHrP-(38-64) incorporated thymidine into DNA 2.5-fold faster than cells from PBS-treated injured lungs (P Ͻ 0.05, Fig. 6 ).
Lung morphology. Injured lungs treated with PTHrP-(38-64) for 4 days contained clusters of cells in the alveolar corners (Fig. 7A) . The appearance was similar to the knobby proliferation of type II cells seen after intratracheal keratinocyte growth factor treatment (31) . Electron microscopy of thin sections in lungs from the same treatment group demonstrated clusters of type II cells (Fig. 7B) . We also stained silica-injured lung for pro-SP-C as a specific type II cell marker. Clusters of SP-C-positive type II cells were present after 4 days of treatment with PTHrP-(38-64) (Fig. 7,  C and D) , but lungs treated with PBS contained predominantly solitary type II cells (Fig. 7E) .
Type II cell numbers. We enumerated type II cells in silica-injured lungs stained for endogenous alkaline phosphatase activity (6) . Alkaline phosphatase was chosen as a marker because the cytochemical stain produces an intense, well-defined reaction product (Fig. 8) that has been used effectively as a type II cell marker after silica injury (23) and 60 Ϯ 10% of type II cells from injured lungs treated with PBS and PTHrP-(38-64), respectively (n ϭ 6 animals/group, P Ͻ 0.01). As an additional test, we compared the distribution of alkaline phosphatase staining and pro-SP-C expression in sections of silicainjured lung that underwent dual staining for both markers (Fig. 10) . The two markers colocalized to the same corner cells.
Effect of PTHrP-(38-64) on Cell Proliferation in Uninjured Lungs
In uninjured animals instilled with PTHrP-(38-64) and treated with subcutaneous PTHrP-(38-64) for 4 days, lungs contained 121 Ϯ 22 PCNA-positive cells/75 hpf (n ϭ 7). PCNA immunoreactivity was significantly less in uninjured animals treated with PBS, 45 Ϯ 14 cells/75 hpf (n ϭ 6, P Ͻ 0.05). However, type II cells isolated from normal lungs were not stimulated to increase DNA synthesis by treatment with PTHrP-(38-64) in vitro. Thymidine uptake in cells treated with 100 nM PTHrP-(38-64) for 24 h was 7,800 Ϯ 920 counts/min (cpm) compared with 8,120 Ϯ 920 cpm in untreated cells. Cell phase values are means Ϯ SE. * P Ͻ 0.05 vs. uninjured type II cells; † P Ͻ 0.05 vs. other type II cell groups; ‡ P Ͻ 0.01 vs. type II cells. Fig. 6 . Thymidine incorporation in type II cells from silica-injured lungs. Type II pneumocytes were isolated from rats 1 day after silica instillation, allowed to adhere in culture for 1 day, and then assayed for incorporation of [ 3 H]thymidine for 24 h. Type II cells isolated from rats treated with intratracheal and subcutaneous PTHrP-(38-64) incorporated thymidine into their DNA 2.5 times faster than cells isolated from injured rats treated with PBS as controls (*P Ͻ 0.05). The data represent results from 3 animals/group.
DISCUSSION
The data presented in this paper indicate that treatment with PTHrP-(38-64) increases the proliferation of alveolar type II cells after injury caused by a single instillation of silica particles. Expression of PCNA by alveolar corner cells is increased; a greater percentage of type II cells is in S phase; isolated type II cells incorporate greater levels of tritiated thymidine into cellular DNA; clusters of type II cells are present in the corners of alveoli in a pattern of knobby proliferation; and the number of alkaline phosphatase-positive cells increases in silica-injured lungs treated with PTHrP-(38-64) compared with injured lungs treated with PBS. The cells expressing PCNA and alkaline phosphatase could conceivably be inflammatory cells, which are present in increased numbers in lungs treated with PTHrP-(38-64). However, PTHrP-(107-138) treatment also increased the influx of inflammatory cells into injured lungs but did not result in increased PCNA expression. Furthermore, PTHrP-(38-64) increased DNA synthesis, as indicated by flow cytometric cell cycle analysis and [ 3 H]thymidine uptake, in type II cells but not in the inflammatory cells from the same lungs. Only a few percent of the inflammatory cells were in S phase in silica-injured lungs, suggesting a lower level of proliferation than in type II cells, irre- spective of treatment. We performed two control studies to demonstrate that the alkaline phosphatase stain was specific for type II cells. In cytospin preparations, the percentage of type II cells expressing alkaline phosphatase was nearly 10-fold higher than the percentage of alkaline phosphatase-positive inflammatory cells. In sections of injured lung, alkaline phosphatase colocalized with pro-SP-C, a specific marker for type II cells, with a high degree of fidelity (Fig. 9) . Thus several lines of evidence suggest that inflammatory cells are not responsible for the increased cell proliferation after PTHrP-(38-64) treatment. To our knowledge, mitogenic effects of PTHrP-(38-64) have not been reported previously.
Although PCNA is expressed in proliferating cells and has been used as a marker for proliferation, it may also be present in cells repairing DNA damage. We cannot exclude this possibility in our model, but the cell cycle analysis, the thymidine incorporation experiments, the histological appearance consistent with type II cell division, and the alkaline phosphatase marker studies indicate that the increase in PCNA expression was accompanied by increased type II cell proliferation. The increased number of alkaline phosphatase-expressing cells suggests that the increased proliferation after PTHrP-(38-64) treatment resulted in an increase in lung type II cell numbers as early as 4 days after the silica injury. More quantitative studies will be necessary to test this hypothesis and to evaluate whether type II cell numbers are altered over a longer period of time. Type II cell numbers peak at ϳ14 days after silica injury in the absence of other experimental manipulations (24, 25) . A decrease in cell death could result in increased type II cell numbers, but PTHrP-(38-64) had no effect on apoptosis of type II cells from injured lungs as measured by fluorescent TUNEL.
Lung PTHrP levels are decreased between 4 and 8 days of exposure to 85% oxygen or 64 h of exposure to 100% oxygen in rats and rabbits (9, 28) . We hypothesized that a fall in lung PTHrP was a general response to injuries of many etiologies, but the decrease in pulmonary PTHrP after silica was modest and greatly abbreviated compared with the changes seen after hyperoxic injury. During exposure to 85% oxygen, lung PTHrP levels are significantly decreased from 4 to 8 days, and the maximal decline is Ͼ80% (9). The difference might be due to differences in the pattern of expression of other growth factors in the two injury models. For example, transforming growth factor (TGF)-␤ expression increases dramatically in silica lung injury but is unchanged between 4 and 8 days of 85% oxygen and decreases during exposure to 100% oxygen (1, 15, 26, 32) . TGF-␤ is a positive regulator of PTHrP expression (34) and may maintain higher levels of PTHrP during silica lung injury. Interleukin-1 and TGF-␣ are upregulated after silica lung injury in rats (15) and are also known to stimulate PTHrP expression (2, 14) .
As described in the introduction, PTHrP-(1-34) is an autocrine inhibitor of type II cell division (12) , and reduction in lung PTHrP-(1-34) levels appears to contribute to the type II cell growth after injury due to 85% oxygen (9) . In the current study, however, PTHrP-(1-34) treatment did not reduce lung cell PCNA expression after silica injury. Other growth factors, such Fig. 10 . Colocalization of pro-SP-C and alkaline phosphatase. This section of lung from a silica-injured rat treated with PTHrP-(38-64) for 4 days was stained for both pro-SP-C and alkaline phosphatase. Pro-SP-C was revealed immunohistochemically with a mouse monoclonal antibody, using 3,3Ј-diaminobenzidine tetrahydrochloride to produce the brown reaction product. Then, the lungs were stained cytochemically for alkaline phosphatase, as described for Fig. 7 (blue reaction product). Arrows denote representative corner cells expressing both markers. The 2 markers colocalized with a high degree of fidelity. as IGF-I, epidermal growth factor, or acidic FGF (16, 22) , have been proposed to regulate pneumocyte proliferation in silica injury and may predominate over PTHrP. Alternatively, the relatively low level of type II cell proliferation in the injured lungs may have hampered our ability to detect a change due to PTHrP-(1-34). Because silica injury at 4 days did not significantly increase PCNA expression over the uninjured state in the absence of exogenous PTHrP treatment, showing a decrease with PTHrP-(1-34) treatment would have been difficult. A longer time course is needed to evaluate adequately the potential inhibitory effects of PTHrP- . Other investigators have shown that type II cell proliferation peaks later in the course of silica injury, between 14 and 28 days (24, 27) .
Peptides other than PTHrP-(1-34) had not been studied in the lung previously, and the growth-stimulatory effects of PTHrP-(38-64) were a new finding. Midmolecule PTHrP peptides are known to have effects in other cell types and organ systems, as discussed in the introduction (17, 33) . The type I PTH/ PTHrP receptor is specific for PTH and PTHrP species containing PTH or PTHrP-(1-34) and does not bind PTHrP-(38-64). Midmolecule PTHrP species are thought to act through yet unidentified receptor(s), receptors that our work suggests should be present on pulmonary cells. Further studies will be needed to determine the mechanism for the effects of PTHrP-(38-64) after silica lung injury. Because PTHrP-(38-64) did not stimulate thymidine incorporation in isolated type II cells, the peptide might be acting in concert with other growth factors released after silica injury, or it could be acting in a paracrine fashion to stimulate other types of cells to express factors regulating type II cell growth. The increased inflammatory cell influx seen after PTHrP-(38-64) treatment could result in increased lung levels of type II cell growth factors derived from those cells. However, growth factor expression by inflammatory cells is unlikely to be the sole mechanism for the effects of PTHrP-(38-64), because all of the PTHrP peptides increased the inflammatory cell population. PTHrP-(107-138) had an effect comparable with PTHrP-(38-64) on cell influx, yet only PTHrP-(38-64) stimulated PCNA expression. An agent might have an indirect effect on type II cell proliferation after lung injury by increasing the severity of the injury. The silica-injured animals treated with PTHrP-(38-64) showed the highest values of lung weight and BAL total protein, suggesting that it might increase the permeability of the alveolocapillary barrier and possibly worsen injury. However, lung weights and protein concentrations were not statistically different from other injured groups, and the high average protein concentration was due, in part, to one outlier value of 800 g/ml. PTHrP-(38-64) did not appear to cause worse lung injury in histological sections, nor did it increase BAL rTI 40 levels, a marker for epithelial damage. PTHrP-(107-138) treatment increased rTI 40 in silica-injured animals treated compared with uninjured animals but did not increase lung PCNA expression, arguing against a potential link between worsened injury and increased proliferation after PTHrP treatment.
The physiological significance of the growth stimulatory effect of PTHrP-(38-64) after silica is unclear. Because lung PTHrP levels fall initially, it would appear unlikely that PTHrP-(38-64) plays an role in increased type II cell proliferation in the first 4 days after injury. While levels of PTHrP measured by an assay specific for PTHrP-(109-141) declined, endogenous PTHrP-(38-64) peptide might have increased in this period. The current study did not investigate PTHrP processing. Further studies are needed using sizing methods to investigate PTHrP processing with and without injury. Because PTHrP levels increase from 4 to 14 days, PTHrP-(38-64) might have a role in stimulating pneumocyte growth in this period. This hypothesis could be tested in future studies by reducing PTHrP levels over this period with neutralizing PTHrP antibodies, as described previously (11) .
In summary, silica lung injury causes modest decreases in lung PTHrP levels. Treating silica-injured lungs with PTHrP-(38-64) increases type II cell proliferation, as evidenced by PCNA expression, formation of clusters of alveolar corner cells, increases in SP-Cpositive and alkaline phosphatase-positive cells, and increases in S phase fraction and thymidine incorporation of type II cells isolated from injured lungs. The increased type II cell proliferation appears to be associated with an increase in type II cell numbers at 4 days after injury and treatment. The mechanisms responsible for the increase in pneumocyte growth and the physiological significance remain to be established.
